NovoCure Ltd Insider Trading for March 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd for March 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 47.04 | 29,969 | 1,409,742 | 29,969 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 0.00 | 16,369 | 0 | 53,204 | 36.8 K to 53.2 K (+44.44 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | A | 47.04 | 37,461 | 1,762,165 | 37,461 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Grant | A | 0.00 | 20,461 | 0 | 86,725 | 66.3 K to 86.7 K (+30.88 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 47.04 | 44,953 | 2,114,589 | 44,953 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Grant | A | 0.00 | 24,554 | 0 | 942,860 | 918.3 K to 942.9 K (+2.67 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 47.04 | 33,783 | 1,589,152 | 33,783 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 18,452 | 0 | 43,691 | 25.2 K to 43.7 K (+73.11 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | A | 47.04 | 44,953 | 2,114,589 | 44,953 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Grant | A | 0.00 | 24,554 | 0 | 258,311 | 233.8 K to 258.3 K (+10.50 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | A | 47.04 | 29,969 | 1,409,742 | 29,969 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Grant | A | 0.00 | 16,369 | 0 | 185,674 | 169.3 K to 185.7 K (+9.67 %) |
| Mar 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 69,743 | |
| Mar 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 48.31 | 5,000 | 241,550 | 60,000 | 65 K to 60 K (-7.69 %) |
| Mar 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 65,000 | 60 K to 65 K (+8.33 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 31,234 | 107,445 | 244,663 | |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 40,000 | 137,600 | 275,897 | |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 18,766 | 64,555 | 315,897 | |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 53.40 | 31,234 | 1,668,021 | 66,264 | 97.5 K to 66.3 K (-32.04 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 31,234 | 107,445 | 97,498 | 66.3 K to 97.5 K (+47.14 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 56.50 | 4,342 | 245,336 | 66,264 | 70.6 K to 66.3 K (-6.15 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 55.95 | 2,800 | 156,654 | 70,606 | 73.4 K to 70.6 K (-3.81 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 54.54 | 2,800 | 152,720 | 73,406 | 76.2 K to 73.4 K (-3.67 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 53.82 | 4,207 | 226,404 | 76,206 | 80.4 K to 76.2 K (-5.23 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 52.90 | 25,851 | 1,367,595 | 80,413 | 106.3 K to 80.4 K (-24.33 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 40,000 | 137,600 | 106,264 | 66.3 K to 106.3 K (+60.36 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 56.52 | 5,222 | 295,153 | 66,264 | 71.5 K to 66.3 K (-7.30 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 56.04 | 4,748 | 266,054 | 71,486 | 76.2 K to 71.5 K (-6.23 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 54.56 | 3,400 | 185,497 | 76,234 | 79.6 K to 76.2 K (-4.27 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 53.91 | 5,396 | 290,877 | 79,634 | 85 K to 79.6 K (-6.35 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 18,766 | 64,555 | 85,030 | 66.3 K to 85 K (+28.32 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 14.37 | 16,268 | 233,771 | 237,609 | |
| Mar 06 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 56.51 | 6,441 | 363,994 | 233,757 | 240.2 K to 233.8 K (-2.68 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 56.00 | 6,127 | 343,124 | 240,198 | 246.3 K to 240.2 K (-2.49 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 54.64 | 3,700 | 202,168 | 246,325 | 250 K to 246.3 K (-1.48 %) |
| Mar 06 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 14.37 | 16,268 | 233,771 | 250,025 | 233.8 K to 250 K (+6.96 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 14.37 | 100,000 | 1,437,000 | 253,877 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 56.49 | 6,903 | 389,923 | 233,757 | 240.7 K to 233.8 K (-2.87 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 55.85 | 55,815 | 3,117,156 | 240,660 | 296.5 K to 240.7 K (-18.83 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 54.97 | 37,282 | 2,049,503 | 296,475 | 333.8 K to 296.5 K (-11.17 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 14.37 | 100,000 | 1,437,000 | 333,757 | 233.8 K to 333.8 K (+42.78 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 21.15 | 16,897 | 357,372 | 45,961 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.15 | 16,250 | 116,188 | 18,514 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.46 | 7,439 | 85,251 | 24 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.09 | 7,736 | 433,943 | 25,239 | 33 K to 25.2 K (-23.46 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 9,161 | 505,990 | 32,975 | 42.1 K to 33 K (-21.74 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 21.15 | 16,897 | 357,372 | 42,136 | 25.2 K to 42.1 K (+66.95 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.10 | 7,517 | 421,681 | 25,239 | 32.8 K to 25.2 K (-22.95 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 8,733 | 482,297 | 32,756 | 41.5 K to 32.8 K (-21.05 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.15 | 16,250 | 116,188 | 41,489 | 25.2 K to 41.5 K (+64.38 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.11 | 3,312 | 185,840 | 25,239 | 28.6 K to 25.2 K (-11.60 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 4,127 | 227,947 | 28,551 | 32.7 K to 28.6 K (-12.63 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.46 | 7,439 | 85,251 | 32,678 | 25.2 K to 32.7 K (+29.47 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 9,260 | 0 | 18,518 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 9,260 | 0 | 18,518 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 53.68 | 3,097 | 166,247 | 918,306 | 921.4 K to 918.3 K (-0.34 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 53.68 | 3,097 | 166,247 | 918,306 | 921.4 K to 918.3 K (-0.34 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 52.90 | 9,260 | 489,854 | 921,403 | 912.1 K to 921.4 K (+1.02 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 52.90 | 9,260 | 489,854 | 921,403 | 912.1 K to 921.4 K (+1.02 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 0.00 | 7,717 | 0 | 15,431 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 0.00 | 7,717 | 0 | 15,431 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 53.68 | 3,288 | 176,500 | 66,264 | 69.6 K to 66.3 K (-4.73 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 53.68 | 3,288 | 176,500 | 66,264 | 69.6 K to 66.3 K (-4.73 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 52.90 | 7,717 | 408,229 | 69,552 | 61.8 K to 69.6 K (+12.48 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 52.90 | 7,717 | 408,229 | 69,552 | 61.8 K to 69.6 K (+12.48 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 0.00 | 6,174 | 0 | 12,345 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 53.68 | 2,397 | 128,671 | 169,305 | 171.7 K to 169.3 K (-1.40 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 52.90 | 6,174 | 326,605 | 171,702 | 165.5 K to 171.7 K (+3.73 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 0.00 | 6,945 | 0 | 13,888 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 52.90 | 6,945 | 367,391 | 152,408 | 145.5 K to 152.4 K (+4.77 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 5,556 | 0 | 11,111 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 53.68 | 2,368 | 127,114 | 36,835 | 39.2 K to 36.8 K (-6.04 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 52.90 | 5,556 | 293,912 | 39,203 | 33.6 K to 39.2 K (+16.51 %) |